Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pinus monticola pollen is an allergenic extract derived from the Western White Pine (*Pinus monticola*). It is a biologic product used primarily for the diagnostic identification of Type I hypersensitivity to Western White Pine pollen. The extract contains various proteins that, when applied via skin prick or intradermal testing, cross-link allergen-specific IgE on mast cells, leading to a localized wheal-and-flare reaction in sensitized individuals. Approved by the FDA under BLAs 101833 and 102192, it is manufactured by specialized allergy laboratories for use in clinical immunology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pinus monticola pollen.